ATH 25.0% 0.5¢ alterity therapeutics limited

I have been able to parse through Biogen's presentation of the...

  1. 114 Posts.
    I have been able to parse through Biogen's presentation of the results of its clinical trial for Alzheimer's disease:

    They are as follows:  Significant reduction in amyloid plaques with 3, 6, and 10 mg at 26 weeks
      Significant reduction in amyloid plaques at 54 weeks with 3 and 10 mg (results for 6 mg not    released yet)
      Significant improvement in cognition (as measured by MMSE scores) at 54 weeks in 3 and 10 mg
      Significant improvement in cognition and function (as measured by CDR-SB) for 10 mg group    only.
      Results for 6 mg group still pending

    No results for cognition/function were reported for 26 weeks; the likely reason Biogen omitted this information was that they were not significant.

    http://www.thestreet.com/story/1308...ers-and-the-biotech-mania-is-it-a-bubble.html

    In the 10mg, 35 percent of the participants with the Apoe4 gene dropped out due to adverse effects.  It would be helpful to know when they dropped out because if it were between 26 and 54 weeks that would bring into question how significant the results for the 10 mg group actually were.

    This was supposed to be a study showing how a particularly effective amyloid antibody was at reducing cognitive decline in early Alzheimer's disease, but irony of ironies it may have just proved the opposite.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
47 58163299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 57489001 48
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 28/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.